The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement system and anaphylatoxin C5a have shown central role in the recruitment of these pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. C5a acts via receptors C5aR and C5L2. This is a preliminary study aimed at studying the expression of the C5a receptor on myeloid cells in peripheral blood of patients with ARDS secondary to COVID-19. This study has of primary objective to show there is an overexpression of the C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers). The medium-term objective is to develop a clinical trial to test the effectiveness of anti-C5aR antibody in this condition.
The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level
of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement
system and anaphylatoxin C5a have shown central role in the recruitment of these
pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. C5a acts
via receptors C5aR and C5L2.
This is a preliminary study aimed at studying the expression of the C5a receptor on myeloid
cells in peripheral blood of patients with ARDS secondary to COVID-19.
This study has of primary objective to show there is an overexpression of the C5a receptor in
patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19
without respiratory distress and healthy volunteers).
The medium-term objective is to develop a clinical trial to test the effectiveness of
anti-C5aR antibody in this condition.
Other: draw blood
40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
Inclusion Criteria:
For patients in resuscitation unit with ARDS linked to COVID-19:
- Patient under invasive mechanical ventilation
- PaO2 / FiO2 <300
- PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample
For control patients with COVID-19 without ARDS
- Oxygen flow always less than 5 L / min
- PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample
- No passage in resuscitation unit
- Favorable evolution
Exclusion Criteria:
- Minors
- Patient deprived of liberty
- Patient's refusal to participate at study
- Patient for whom therapeutic limitation measures such as non-admission to intensive
care have been issued
- Medullar aplasia
Assistance Publique Hôpitaux de Marseille
Marseille, France
Investigator: Julien CARVELLI
Contact: 04 13 42 95 35
Julien.CARVELLI@ap-hm.fr
Investigator:
Julien JC CARVELLI, MD
04 13 42 95 35 - +33
Julien.CARVELLI@ap-hm.fr
Kahéna KA AMICHI
04 91 38 19 66 - +33
Kahena.AMICHI@ap-hm.fr
Emilie EGP GARRIDO-PRADALIE, Study Director
Assistance Publique Hôpitaux de Marseille